{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:05:46Z","timestamp":1773032746819,"version":"3.50.1"},"reference-count":86,"publisher":"Elsevier","isbn-type":[{"value":"9780128177501","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"am","delay-in-days":739,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004794","name":"Centre National de la Recherche Scientifique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.apcsb.2019.07.002","type":"book-chapter","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T18:47:22Z","timestamp":1574794042000},"page":"249-272","source":"Crossref","is-referenced-by-count":3,"title":["Misfolding of vasopressin receptors: biased agonist pharmacochaperones as potential therapeutics"],"prefix":"10.1016","member":"78","reference":[{"issue":"10","key":"10.1016\/bs.apcsb.2019.07.002_bib1","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1681\/ASN.V9101861","article-title":"Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotype","volume":"9","author":"Ala","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.07.002_bib2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/eurjhf\/hfq226","article-title":"Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine-vasopressin V2 receptor antagonist: The DILIPO study","volume":"13","author":"Aronson","year":"2011","journal-title":"European Journal of Heart Failure"},{"issue":"51","key":"10.1016\/bs.apcsb.2019.07.002_bib3","doi-asserted-by":"crossref","first-page":"42198","DOI":"10.1074\/jbc.M510180200","article-title":"Mechanisms of cell-surface rerouting of an endoplasmic reticulum-retained mutant of the vasopressin V1b\/V3 receptor by a pharmacological chaperone","volume":"280","author":"Auzan","year":"2005","journal-title":"The Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.07.002_bib4","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.coph.2004.08.001","article-title":"Pharmacological chaperone action on G protein-coupled receptors","volume":"4","author":"Bernier","year":"2004","journal-title":"Current Opinion in Pharmacology"},{"issue":"8","key":"10.1016\/bs.apcsb.2019.07.002_bib5","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1210\/me.2004-0080","article-title":"Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059","volume":"18","author":"Bernier","year":"2004","journal-title":"Molecular Endocrinology"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.07.002_bib6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1681\/ASN.2005080854","article-title":"Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus","volume":"17","author":"Bernier","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.07.002_bib7","first-page":"278","article-title":"Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insipidus","volume":"55","author":"Bichet","year":"1994","journal-title":"American Journal of Human Genetics"},{"issue":"6376","key":"10.1016\/bs.apcsb.2019.07.002_bib8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/357333a0","article-title":"Molecular cloning of the receptor for human antidiuretic hormone","volume":"357","author":"Birnbaumer","year":"1992","journal-title":"Nature"},{"issue":"8","key":"10.1016\/bs.apcsb.2019.07.002_bib9","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00467-013-2526-4","article-title":"Urinary concentration: Different ways to open and close the tap","volume":"29","author":"Bockenhauer","year":"2014","journal-title":"Pediatric Nephrology"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.07.002_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000245059","article-title":"Vasopressin type 2 receptor V88M mutation: Molecular basis of partial and complete nephrogenic diabetes insipidus","volume":"114","author":"Bockenhauer","year":"2010","journal-title":"Nephron Physiology"},{"key":"10.1016\/bs.apcsb.2019.07.002_bib11","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev.med.57.110104.115650","article-title":"Enzyme replacement for lysosomal diseases","volume":"57","author":"Brady","year":"2006","journal-title":"Annual Review of Medicine"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.07.002_bib12","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1124\/jpet.105.088914","article-title":"Characterization of isoprenaline- and salmeterol-stimulated interactions between beta2-adrenoceptors and beta-arrestin 2 using beta-galactosidase complementation in C2C12 cells","volume":"315","author":"Carter","year":"2005","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.07.002_bib13","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1742-4658.2006.05181.x","article-title":"Protein-misfolding diseases and chaperone-based therapeutic approaches","volume":"273","author":"Chaudhuri","year":"2006","journal-title":"FEBS Journal"},{"issue":"16","key":"10.1016\/bs.apcsb.2019.07.002_bib14","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.1021\/jm300603y","article-title":"Structure-functional selectivity relationship studies of \u03b2-arrestin-biased dopamine D2 receptor agonists","volume":"55","author":"Chen","year":"2012","journal-title":"Journal of Medicinal Chemistry"},{"issue":"6968","key":"10.1016\/bs.apcsb.2019.07.002_bib15","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nature02265","article-title":"Therapeutic approaches to protein-misfolding diseases","volume":"426","author":"Cohen","year":"2003","journal-title":"Nature"},{"issue":"8","key":"10.1016\/bs.apcsb.2019.07.002_bib16","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1177\/1087057113483559","article-title":"High-throughput screen for pharmacoperones of the vasopressin type 2 receptor","volume":"18","author":"Conn","year":"2013","journal-title":"Journal of Biomolecular Screening"},{"key":"10.1016\/bs.apcsb.2019.07.002_bib17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.phrs.2013.12.004","article-title":"Transitioning pharmacoperones to therapeutic use: In vivo proof-of-principle and design of high throughput screens","volume":"83","author":"Conn","year":"2014","journal-title":"Pharmacological Research"},{"issue":"8","key":"10.1016\/bs.apcsb.2019.07.002_bib18","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.tips.2015.05.004","article-title":"Assay strategies for identification of therapeutic leads that target protein trafficking","volume":"36","author":"Conn","year":"2015","journal-title":"Trends in Pharmacological Sciences"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.07.002_bib19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/pr.59.3.2","article-title":"G protein-coupled receptor trafficking in health and disease: Lessons learned to prepare for therapeutic mutant rescue in vivo","volume":"59","author":"Conn","year":"2007","journal-title":"Pharmacological Reviews"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.07.002_bib20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.tem.2009.11.003","article-title":"Trafficking of G protein-coupled receptors to the plasma membrane: Insights from pharmacoperone drugs","volume":"21","author":"Conn","year":"2010","journal-title":"Trends in Endocrinology and Metabolism"},{"key":"10.1016\/bs.apcsb.2019.07.002_bib21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/B978-0-12-385952-5.00008-7","article-title":"Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors","volume":"62","author":"Conn","year":"2011","journal-title":"Advances in Pharmacology"},{"issue":"39","key":"10.1016\/bs.apcsb.2019.07.002_bib22","doi-asserted-by":"crossref","first-page":"27849","DOI":"10.1074\/jbc.M112.445098","article-title":"Noncanonical control of vasopressin receptor type 2 signaling by retromer and arrestin","volume":"288","author":"Feinstein","year":"2013","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.07.002_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0031-6997(24)01478-9","article-title":"Evolving concepts in G protein-coupled receptor endocytosis: The role in receptor desensitization and signaling","volume":"53","author":"Ferguson","year":"2001","journal-title":"Pharmacological Reviews"},{"issue":"8","key":"10.1016\/bs.apcsb.2019.07.002_bib24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.tips.2007.06.005","article-title":"The evasine nature of drug efficacy: Implications for drug discovery","volume":"28","author":"Galandrin","year":"2007","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/bs.apcsb.2019.07.002_bib25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1750-1172-7-91","article-title":"Safety and pharmacodynamic effects of a pharmacological chaperone on \u03b1-galactosidase a activity and globotriaosylceramide clearance in Fabry disease: Report from two phase 2 clinical studies","volume":"7","author":"Germain","year":"2012","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"6","key":"10.1016\/bs.apcsb.2019.07.002_bib26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry's disease with the pharmacologic chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.07.002_bib27","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1124\/mol.106.028258","article-title":"An opioid agonist that does not induce mu-opioid receptor-arrestin interactions or receptor internalization","volume":"71","author":"Groer","year":"2007","journal-title":"Molecular Pharmacology"},{"issue":"21","key":"10.1016\/bs.apcsb.2019.07.002_bib28","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1074\/jbc.M511610200","article-title":"Pharmacological chaperone activity of SR49059 to functionally recover misfolded mutations of the vasopressin V1a receptor","volume":"281","author":"Hawtin","year":"2006","journal-title":"The Journal of Biological Chemistry"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.07.002_bib29","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0026-895X(24)12327-9","article-title":"Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors","volume":"61","author":"Holloway","year":"2002","journal-title":"Molecular Pharmacology"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.07.002_bib30","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1210\/jcem.87.7.8582","article-title":"Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: Misrouted proteins as a novel disease etiology and therapeutic target","volume":"87","author":"Janovick","year":"2002","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"1\u20132","key":"10.1016\/bs.apcsb.2019.07.002_bib31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.mce.2008.09.015","article-title":"Increased plasma membrane expression of human follicle-stimulating hormone receptor by a small molecule thienopyr(im)idine","volume":"298","author":"Janovick","year":"2009","journal-title":"Molecular and Cellular Endocrinology"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.07.002_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022784","article-title":"Therapeutic rescue of misfolded mutants: Validation of primary high throughput screens for identification of pharmacoperone drugs","volume":"6","author":"Janovick","year":"2011","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/bs.apcsb.2019.07.002_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181830","article-title":"Pharmacoperone rescue of vasopressin 2 receptor mutants reveals unexpected constitutive activity and coupling bias","volume":"12","author":"Janovick","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/bs.apcsb.2019.07.002_bib34","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.mce.2016.07.003","article-title":"Receptor antagonism\/agonism can be can be uncoupled from pharmacoperone activity","volume":"434","author":"Janovick","year":"2016","journal-title":"Molecular and Cellular Endocrinology"},{"issue":"52","key":"10.1016\/bs.apcsb.2019.07.002_bib35","doi-asserted-by":"crossref","first-page":"21030","DOI":"10.1073\/pnas.1315194110","article-title":"Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy","volume":"110","author":"Janovick","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"10","key":"10.1016\/bs.apcsb.2019.07.002_bib36","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1681\/ASN.2008121289","article-title":"Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital Nephrogenic Diabetes Insipidus","volume":"20","author":"Jean-Alphonse","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.07.002_bib37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1006\/excr.1997.3581","article-title":"Lysosomal biogenesis in lysosomal storage disorders","volume":"234","author":"Karageorgos","year":"1997","journal-title":"Experimental Cell Research"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.07.002_bib38","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1073\/pnas.93.1.116","article-title":"The human thyrotropin receptor: A heptahelical receptor capable of stimulating members of all four G protein families","volume":"93","author":"Laugwitz","year":"1996","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.apcsb.2019.07.002_bib39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.phrs.2014.01.005","article-title":"Pharmacological chaperoning: A primer on mechanism and pharmacology","volume":"83","author":"Leidenheimer","year":"2014","journal-title":"Pharmacological Research"},{"issue":"6072","key":"10.1016\/bs.apcsb.2019.07.002_bib40","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1126\/science.1215802","article-title":"Biased signaling pathways in \u03b22-adrenergic receptor characterized by 19F-NMR","volume":"335","author":"Liu","year":"2012","journal-title":"Science"},{"issue":"6376","key":"10.1016\/bs.apcsb.2019.07.002_bib41","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/357336a0","article-title":"Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus","volume":"357","author":"Lolait","year":"1992","journal-title":"Nature"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.07.002_bib42","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1074\/jbc.272.2.709","article-title":"Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators","volume":"272","author":"Loo","year":"1997","journal-title":"The Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.07.002_bib43","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-2826.2010.01983.x","article-title":"Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus","volume":"22","author":"Los","year":"2010","journal-title":"Journal of Neuroendocrinology"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.07.002_bib44","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1210\/me.2013-1314","article-title":"More than just a hammer : Ligand \"bias\" and pharmaceutical discovery","volume":"28","author":"Lutrell","year":"2014","journal-title":"Molecular Endocrinology"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.07.002_bib45","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1124\/pr.109.002436","article-title":"Beyond desensitization: Physiological relevance of arrestin-dependent signaling","volume":"62","author":"Luttrell","year":"2010","journal-title":"Pharmacological Reviews"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.07.002_bib46","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1124\/mol.115.099630","article-title":"Fulfilling the promise of \"biased\" G protein-coupled receptor agonism","volume":"88","author":"Luttrell","year":"2015","journal-title":"Molecular Pharmacology"},{"issue":"21","key":"10.1016\/bs.apcsb.2019.07.002_bib47","doi-asserted-by":"crossref","first-page":"8304","DOI":"10.1073\/pnas.1119881109","article-title":"Ligands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor","volume":"109","author":"Mary","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6\u20137","key":"10.1016\/bs.apcsb.2019.07.002_bib48","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1051\/medsci\/2010266-7627","article-title":"Pharmacological chaperones: A potential therapeutic treatment for conformational diseases","volume":"26","author":"Mendre","year":"2010","journal-title":"M\u00e9decine\/Sciences (Paris)"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.07.002_bib49","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1210\/er.2012-1044","article-title":"Nephrogenic diabetes insipidus: Essential insights into the molecular background and potential therapies for treatment","volume":"34","author":"Moeller","year":"2013","journal-title":"Endocrine Reviews"},{"key":"10.1016\/bs.apcsb.2019.07.002_bib50","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1146\/annurev.physiol.63.1.607","article-title":"Nephrogenic diabetes insipidus","volume":"63","author":"Morello","year":"2001","journal-title":"Annual Review of Physiology"},{"issue":"12","key":"10.1016\/bs.apcsb.2019.07.002_bib51","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0165-6147(00)01575-3","article-title":"Pharmacological chaperones: A new twist on receptor folding","volume":"21","author":"Morello","year":"2000","journal-title":"Trends in Pharmacological Sciences"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.07.002_bib52","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1172\/JCI8688","article-title":"Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants","volume":"105","author":"Morello","year":"2000","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/bs.apcsb.2019.07.002_bib53","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2013.10.007","article-title":"Vasopressin receptors and pharmacological chaperones: From functional rescue to promising therapeutic strategies","volume":"83","author":"Mouillac","year":"2014","journal-title":"Pharmacological Research"},{"issue":"17","key":"10.1016\/bs.apcsb.2019.07.002_bib54","doi-asserted-by":"crossref","first-page":"7172","DOI":"10.1073\/pnas.1015723108","article-title":"Rescue of expression and signaling of human luteinizing hormone G protein-coupled receptor mutants with an allosterically binding small-molecule agonist","volume":"108","author":"Newton","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.07.002_bib55","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0026-895X(25)10203-4","article-title":"Transfected muscarinic acetylcholine receptors selectively couple to Gi-type G proteins and Gq\/11","volume":"45","author":"Offermanns","year":"1994","journal-title":"Molecular Pharmacology"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.07.002_bib56","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/mt.2015.62","article-title":"Pharmacological chaperone therapy: Preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders","volume":"23","author":"Parenti","year":"2015","journal-title":"Molecular Therapy"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.07.002_bib57","first-page":"102","article-title":"Lysosomal storage disease: Revealing lysosomal function and physiology","volume":"25","author":"Parkinson-Lawrence","year":"2010","journal-title":"Physiology (Bethesda)"},{"issue":"457","key":"10.1016\/bs.apcsb.2019.07.002_bib58","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1651-2227.2008.00656.x","article-title":"Substrate reduction therapy","volume":"97","author":"Platt","year":"2008","journal-title":"Acta Paediatrica"},{"issue":"17","key":"10.1016\/bs.apcsb.2019.07.002_bib59","doi-asserted-by":"crossref","first-page":"6733","DOI":"10.1073\/pnas.1201093109","article-title":"Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy","volume":"109","author":"Rahmeh","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.07.002_bib60","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrd3024","article-title":"Teaching old receptors new tricks: Biasing seven-transmembrane receptors","volume":"9","author":"Rajagopal","year":"2010","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/bs.apcsb.2019.07.002_bib61","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev.pharmtox.010909.105800","article-title":"Molecular mechanism of \u03b2-arrestin-biased agonism at seven-transmembrane receptors","volume":"52","author":"Reiter","year":"2012","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"29","key":"10.1016\/bs.apcsb.2019.07.002_bib62","doi-asserted-by":"crossref","first-page":"12195","DOI":"10.1073\/pnas.0900130106","article-title":"Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists","volume":"106","author":"Robben","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.07.002_bib63","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1091\/mbc.e05-06-0579","article-title":"Rescue of vasopressin V2 receptor mutants by chemical chaperones: Specificity and mechanism","volume":"17","author":"Robben","year":"2006","journal-title":"Molecular Biology of the Cell"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.07.002_bib64","doi-asserted-by":"crossref","first-page":"F253","DOI":"10.1152\/ajprenal.00247.2006","article-title":"Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: Relevance to therapy of nephrogenic diabetes insipidus","volume":"292","author":"Robben","year":"2007","journal-title":"American Journal of Physiology-Renal Physiology"},{"issue":"6392","key":"10.1016\/bs.apcsb.2019.07.002_bib65","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/359233a0","article-title":"Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus","volume":"359","author":"Rosenthal","year":"1992","journal-title":"Nature"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.07.002_bib66","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0022-3565(25)12378-1","article-title":"Tachykinin peptides affect differently the second messenger pathways after binding to CHO-expressed human NK-1 receptors","volume":"276","author":"Sagan","year":"1996","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.07.002_bib67","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1074\/jbc.271.2.635","article-title":"Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation","volume":"271","author":"Sato","year":"1996","journal-title":"The Journal of Biological Chemistry"},{"issue":"20","key":"10.1016\/bs.apcsb.2019.07.002_bib68","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1016\/bs.apcsb.2019.07.002_bib69","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1172\/JCI119098","article-title":"Characterization of SR 121463A, a highly potent and selective, orally active\u00a0vasopressin V2 receptor antagonist","volume":"98","author":"Serradeil-Le Gal","year":"1996","journal-title":"The Journal of Clinical Investigation"},{"issue":"9","key":"10.1016\/bs.apcsb.2019.07.002_bib70","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.tips.2011.05.002","article-title":"\u03b2-arrestin-mediated receptor trafficking and signal transduction","volume":"32","author":"Shenoy","year":"2011","journal-title":"Trends in Pharmacological Sciences"},{"issue":"8","key":"10.1016\/bs.apcsb.2019.07.002_bib71","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1177\/1087057116653925","article-title":"Identification of potential pharmacoperones capable of rescuing the functionality of misfolded vasopressin 2 receptor involved in Nephrogenic Diabetes Insipidus","volume":"21","author":"Smith","year":"2016","journal-title":"Journal of Biomolecular Screening"},{"key":"10.1016\/bs.apcsb.2019.07.002_bib72","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/B978-0-12-391862-8.00001-6","article-title":"Therapeutic rescue of misfolded.mistrafficked mutants: Automation-friendly high-throughput assays for identification of pharmacoperone drugs of GPCRs","volume":"521","author":"Smithson","year":"2013","journal-title":"Methods in Enzymology"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.07.002_bib73","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/jcp.21552","article-title":"AVPR2 variants and mutations in Nephrogenic Diabetes Insipidus ; review and missense mutation significance","volume":"217","author":"Spanakis","year":"2008","journal-title":"Journal of Cellular Physiology"},{"issue":"41","key":"10.1016\/bs.apcsb.2019.07.002_bib74","doi-asserted-by":"crossref","first-page":"13453","DOI":"10.1021\/bi990437n","article-title":"Amino-terminal modifications of human parathyroid hormone (PTH) selectively alter phospholipase C signaling via the type 1 PTH receptor: Implications for design of signal-specific PTH ligands","volume":"38","author":"Takasu","year":"1999","journal-title":"Biochemistry"},{"issue":"10","key":"10.1016\/bs.apcsb.2019.07.002_bib75","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1172\/JCI2303","article-title":"Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones","volume":"101","author":"Tamarappoo","year":"1998","journal-title":"The Journal of Clinical Investigation"},{"issue":"37","key":"10.1016\/bs.apcsb.2019.07.002_bib76","doi-asserted-by":"crossref","first-page":"35678","DOI":"10.1074\/jbc.M301888200","article-title":"Appropriate polarization following pharmacological rescue of V2 vasopressin receptors encoded by X-linked nephrogenic diabetes insipidus alleles involves a conformation of the receptor that also attains mature glycosylation","volume":"278","author":"Tan","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.07.002_bib77","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1124\/jpet.103.061754","article-title":"A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties","volume":"309","author":"Thurmond","year":"2004","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"25","key":"10.1016\/bs.apcsb.2019.07.002_bib78","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.07.002_bib79","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/00000542-200609000-00026","article-title":"The vasopressin system","volume":"105","author":"Treschan","year":"2006","journal-title":"Anesthesiology"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.07.002_bib80","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1172\/JCI118252","article-title":"Binding, intracellular transport and biosynthesis-defective mutants of vasopressin type 2 receptor in patients with X-linked nephrogenic diabetes insipidus","volume":"96","author":"Tsukagushi","year":"1995","journal-title":"The Journal of Clinical Investigation"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.07.002_bib81","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1124\/jpet.110.173005","article-title":"Selectively engaging \u03b2-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance","volume":"335","author":"Violin","year":"2010","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"12","key":"10.1016\/bs.apcsb.2019.07.002_bib82","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1007\/s00467-012-2118-8","article-title":"Congenital nephrogenic diabetes insipidus : The current state of affairs","volume":"27","author":"Wesche","year":"2012","journal-title":"Pediatric Nephrology"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.07.002_bib83","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1210\/me.2009-0041","article-title":"Pharmacochaperone-mediated rescue of calcium-sensing receptor loss-of-function mutants","volume":"23","author":"White","year":"2009","journal-title":"Molecular Endocrinology"},{"issue":"42","key":"10.1016\/bs.apcsb.2019.07.002_bib84","doi-asserted-by":"crossref","first-page":"16657","DOI":"10.1073\/pnas.0707936104","article-title":"A unique mechanism of beta-blocker action : Carvedilol stimulates beta-arrestin signaling","volume":"104","author":"Wisler","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"45","key":"10.1016\/bs.apcsb.2019.07.002_bib85","doi-asserted-by":"crossref","first-page":"47254","DOI":"10.1074\/jbc.M408154200","article-title":"Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors","volume":"279","author":"W\u00fcller","year":"2004","journal-title":"The Journal of Biological chemistry"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.07.002_bib86","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bcmd.2012.09.006","article-title":"Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease","volume":"50","author":"Zimran","year":"2013","journal-title":"Blood Cells, Molecules, and Diseases"}],"container-title":["Advances in Protein Chemistry and Structural Biology","Protein Misfolding"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162319300549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162319300549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:21:08Z","timestamp":1761754868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876162319300549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780128177501"],"references-count":86,"URL":"https:\/\/doi.org\/10.1016\/bs.apcsb.2019.07.002","relation":{},"ISSN":["1876-1623"],"issn-type":[{"value":"1876-1623","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}